1. Scrip
  2. >>R&D

Freeze Lift Allows Cel-Sci And Ergomed Motor On With Multikine

 
• By Sten Stovall

The biggest Phase III trial in head and neck cancer is resuming after the FDA lifted a freeze on trials evaluating CEL-SCI's lead asset Multikine in the indication, giving a boost to its commercial prospects.

Skull
FDA Lifted Its Freeze On The Multikine Phase III Clinical Trial In Head And Neck Cancer • Source: Shutterstock

Cel-Sci Corp. and Ergomed PLC have voiced relief at the FDA's decision to remove the clinical hold placed on a Phase III study evaluating Multikine (Leukocyte Interleukin, Injection) in head and neck cancer, the biggest-ever drug trial for that condition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D